Invion (IVIXF) Stock Price & Analysis
IVIXF Stock Chart & Stats
- Day’s Range
- $0.04 - $0.04
- 52-Week Range
- $0.04 - $0.04
- Previous Close
- $0.04
- Volume
- 10
- Average Volume (3M)
- 0
- Market Cap
- $2.64M
- Enterprise Value
- $4.42M
- Total Cash (Recent Filing)
- $592.31K
- Total Debt (Recent Filing)
- $1.55M
- Price to Earnings (P/E)
- ―
- Beta
- -3.67
- Next Earnings
- Feb 24, 2027 (Est.)
- EPS Estimate
- N/A
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Proprietary Cancer Therapy Platform
A proprietary light-activated therapy platform gives Invion a defined technological base rather than a broad, undifferentiated research strategy. If development continues to show efficacy, the platform could support multiple cancer applications and create longer-term partnering or commercialization opportunities.
Potentially Broad Clinical Applications
Application across breast and ovarian cancer indicates that the platform is being investigated beyond a single disease setting. The potential to selectively destroy cancer cells while stimulating immune responses could broaden the addressable opportunity, although the pack does not establish clinical success.
Moderate Reported Leverage
Debt is described as moderate relative to reported equity, so leverage is not identified as the primary balance-sheet issue. This provides somewhat more financial flexibility than a highly debt-dependent structure, even though continuing losses and equity erosion remain important constraints.
Bears Say
Persistent Unprofitability
Persistent operating and net losses show that the current business has not yet converted its research activity into a profitable earnings base. Continued losses can consume capital, restrict investment choices, and make future growth dependent on improving economics or obtaining additional funding.
Unstable And Very Low Revenue
The sharp collapse in revenue and only limited recovery indicate an unstable commercial base rather than a dependable growth trajectory. Such a low and volatile revenue run-rate reduces operating leverage, makes costs harder to support, and limits visibility into near-term business sustainability.
Ongoing Cash Burn And Equity Erosion
Negative operating cash flow means operations continue to consume cash, while the substantial fall in equity reflects the cumulative effect of losses and possible capital depletion. Together, these trends weaken financial resilience and may constrain the company’s ability to fund development internally.
Invion News
IVIXF FAQ
What was Invion’s price range in the past 12 months?
What is Invion’s market cap?
When is Invion’s upcoming earnings report date?
How were Invion’s earnings last quarter?
Is Invion overvalued?
Does Invion pay dividends?
What is Invion’s EPS estimate?
How many shares outstanding does Invion have?
What happened to Invion’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Invion?
What is the TipRanks Smart Score and how is it calculated?
Invion Stock Smart Score
Company Description
Invion
Invion Limited, an Australian clinical-stage life sciences enterprise, is actively engaged in the research and development of photodynamic therapy (PDT) to address various cancer types. Its flagship offering, IVX-PDT, is a photosensitizer agent being developed to combat skin cancers alongside a range of solid tumors, including those affecting the lungs, prostate, ovaries, and mesothelioma. The company has forged a research and development alliance with the Hudson Institute of Medical Research, jointly pursuing R&D initiatives for its Photosoft technology across a broad spectrum of cancer treatments. Moreover, a dedicated research agreement with the Peter MacCallum Cancer Centre facilitates pre-clinical and in-vitro investigations into Invion's IVX-PDT for ano-genital cancers, such as penile and anal cancers. The firm was established in 2000 and is headquartered in Melbourne, Australia.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- CEO
- Thian Chew
- Employees
- 8
- Website
- www.inviongroup.com
- Address
- 385 Bourke Street, Melbourne, VIC, 3000, AU
Invion (IVIXF) Earnings & Revenues
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 3 | 3 | 10 |
| Technical Analysis | 1 | 1 | 2 |
| Moving Averages | 2 | 2 | 8 |






